Mehmet Cilingiroglu

ORCID: 0000-0002-6557-2267
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Coronary Interventions and Diagnostics
  • Peripheral Artery Disease Management
  • Cardiac Valve Diseases and Treatments
  • Cerebrovascular and Carotid Artery Diseases
  • Cardiac pacing and defibrillation studies
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Cardiac Imaging and Diagnostics
  • Cardiovascular Function and Risk Factors
  • Healthcare and Venom Research
  • Mechanical Circulatory Support Devices
  • Venous Thromboembolism Diagnosis and Management
  • Acute Kidney Injury Research
  • Economic and Financial Impacts of Cancer
  • Chemotherapy-induced cardiotoxicity and mitigation
  • Ocular Diseases and Behçet’s Syndrome
  • Kawasaki Disease and Coronary Complications
  • Cardiac Arrest and Resuscitation
  • Advanced Breast Cancer Therapies
  • Cardiac Health and Mental Health
  • Pharmaceutical Economics and Policy
  • Acute Myocardial Infarction Research
  • Renal and Vascular Pathologies
  • Health Systems, Economic Evaluations, Quality of Life
  • Atrial Fibrillation Management and Outcomes
  • Retinal and Optic Conditions

The University of Texas MD Anderson Cancer Center
2024-2025

The University of Texas Health Science Center at San Antonio
2024

The absence of a Food and Drug Administration-approved percutaneous valve technology for the treatment severe aortic regurgitation (AR) presents challenge high-risk patients. In this report, we describe successful an 84-year-old male patient suffering from symptomatic AR concomitant cardiorenal syndrome with renal failure using 34 mm Evolut R (Medtronic) self-expanding transcatheter replacement. This intervention resulted in resolution AR, syndrome, congestive heart symptoms.

10.15420/usc.2024.19 article EN cc-by-nc US Cardiology Review 2024-11-13
Coming Soon ...